Italia markets closed

Medigene AG (0QGJ.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
2,2500+0,0200 (+0,90%)
Alla chiusura: 11:45AM GMT

Medigene AG

Lochhamer Strasse 11
Planegg/Martinsried
Munich 82152
Germany
49 89 2000 330
https://www.medigene.com

Settore/i
Settore
Impiegati a tempo pieno87

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Selwyn Ho MB BS, MBBSCEO & Member of Executive Management Board384,47kN/D1971
Dr. Dolores J. SchendelChief Scientific Officer, Member of Executive Management Board and Head of Research & Development600kN/DN/D
Dr. Ernst-Ludwig WinnackerCo-Founder & Chairman Scientific Advisory Board20kN/D1941
Dr. Birger KohlertChief Financial OfficerN/DN/DN/D
Pamela KeckVice President of Investor Relations & Corporate CommunicationsN/DN/DN/D
Dr. Kirsty Crame M.D.VP and Head of Clinical Research & DevelopmentN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Governance aziendale

L'ISS Governance QualityScore di Medigene AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.